Mimedx Group, Inc · NASDAQ:MDXG
Mimedx — Investor Presentation (July 2024)
15 slides from Mimedx's investor presentation, Jul 31, 2024
Slide 1: Investor Presentation August 2024
Exhibit 99.3 Investor Presentation August 2024 helping humans heal.
Slide 2: Disclaimer & Cautionary Statements
Disclaimer & Cautionary Statements This presentation includes forward-looking statements. Forward-looking statements are subject to risks and uncertainties, and the Company cautions investors against placing undue reliance on such statements. Actual results may differ materially from those set forth
Slide 3: Disclaimer & Cautionary Statements
Disclaimer & Cautionary Statements Additional forward-looking statements may be identified by words such as believe, expect, may, plan, potential, will, preliminary, and similar expressions, and are based on management's current beliefs and expectations. Forward-looking statements are subject to ris
Slide 4: A Pioneer and Leader in Healing Solutions for Wound & Surgical
A Pioneer and Leader in Healing Solutions for Wound & Surgical To be the leading global Helping Our Our provider of healing solutions Humans through relentless innovation Why Vision Heal to restore quality of life. Large, national placental New product innovations The most studied portfolio A key pa
Slide 5: The Unmet Need for Wound Healing Solutions Is Large and Growing
The Unmet Need for Wound Healing Solutions Is Large and Growing 1 million people suffer from chronic, non-healing wounds in the U.S. >10 • Aging population Favorable • Obesity Demographic • Smoking history• Heart & vascular disease Trends • Diabetes Chronic Wounds ~16% of the Medicare beneficiary po
Slide 6: The Patient Journey in Wound Care
The Patient Journey in Wound Care MIMEDX products are available in all settings …and are used on a range of chronic and other where patients receive care… hard-to-heal wounds. Private Acute Wounds Office Wound Hospital Care Clinic Inpatient Mohs surgery Burn/Trauma Hospital Home Chronic Wounds Outpa
Slide 7: Significant Opportunity to Drive Further Utilization in Surgical
Significant Opportunity to Drive Further Utilization in Surgical Neuro Mohs Orthopedic Spine Colorectal Anastomoses Procedures Cranioplasty Procedures with AMNIOFIX® with AMNIOFIX Gastrointestinal 3 1 Anastomotic Leak Rate with & without AMNIOFIX Clinical Outcomes with Conventional Methods 4% OB/GYN
Slide 8: Our Strategic Priorities
Our Strategic Priorities • Continue momentum with new organic products in Wound & Surgical Innovate & Diversify Build leadership position Product Portfolio to • Consider additional inorganic additions in Wound & Surgical Maximize Growth to our product offering • Drive further uptake of EPIFIX® in Ja
Slide 9: Advanced Wound Care Market by Technology Platform
Advanced Wound Care Market by Technology Platform Current MIMEDX Product Offering Placental-derived allografts Animal-derived xenografts Synthetically manufactured grafts Section 361 regulatory pathway; FDA 510(k) regulatory pathway; claims FDA 510(k) regulatory pathway; claims homologous use; barri
Slide 10: Expanding Breadth of Skin Substitutes
Expanding Breadth of Skin Substitutes Leading Human-Derived Portfolio Emerging Xenograft Platform Best-in-Class Wound Product Portfolio Recently announced exclusive manufacturing and supply agreement with Regenity Biosciences. HELIOGEN builds on our goal to augment our growth through strategic portf
Slide 11: Physician Office Medicare Reimbursement Overhaul Underway
Physician Office Medicare Reimbursement Overhaul Underway 1 Increasing the number of skin substitutes on the Medicare Medicare Allowed Charges for skin substitutes have Resulting in a de-facto national 2 ASP List has proven insufficient, with a significant number exploded since 2020 coverage proposa
Slide 12: Diversified Business by Product & Across Multiple Sites of Service
Diversified Business by Product & Across Multiple Sites of Service Product Type Segment Commentary Led by best-in-class placental allograft, 35% Wound EPIFIX and our newest product innovation, EPIEFFECT® 65% Continuing to see expanding use cases for Surgical allografts and xenografts in a large and
Slide 13: Q2:24 Highlights
Q2:24 Highlights 1 Net Income Net Sales Gross Margin Adjusted EBITDA $18MM $87MM 83% $20MM +7% year-over-year 23% of net sales Portfolio Expansion First Publication Cash Balance Free Cash Flow into Xenografts in 1 $69MM $21MM 13 1 – EBITDA, Adjusted EBITDA, related margins and Free Cash Flow are non
Slide 14: Management Team with Track Record of Success in MedTech
Management Team with Track Record of Success in MedTech Doug Rice Kim Moller Joe Capper John Harper, Ph.D. Butch Hulse Kate Surdez Matt Notarianni Ricci Whitlow Chief Financial Chief Commercial Chief Executive Chief Scientific Officer & Chief Administrative Chief Human Head of IR Chief Operating Off
Slide 15: Conclusion
Conclusion Committed to Pioneer Expanding and leader presence in delivering above- in Advanced Wound & market growth Wound Care Surgical and profitability helping humans heal. 15